Stock Financial Ratios


CASC / Cascadian Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.10
Volume230,800.00
Market Cap ($M)198.59
Enterprise Value ($M)65.88
Book Value ($M)74.36
Book Value / Share3.86
Price / Book1.64
NCAV ($M)74.49
NCAV / Share3.87
Price / NCAV1.66
Income Statement (mra) ($M)
Revenue0.00
EBITDA-64.83
Net Income-57.70
Balance Sheet (mrq) ($M)
Cash & Equivalents12.74
Cash / Share0.66
Assets133.39
Liabilities8.77
Quick Ratio7.35
Current Ratio7.35
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.78
Return on Assets (ROA)-0.69
Return on Equity (ROE)-0.78
Identifiers and Descriptors
CUSIP14740B101
Central Index Key (CIK)1412067
Industry Groups
SIC 8731 - Commercial Physical and Biological Research
Other Related CUSIPS
14740B606
147195101
14740B956
14740B901
14740B906
14740B951
Share Statistics
Common Shares Outstanding (M)50.56
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.07
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Liabilities Current Per Share0.45
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Retained Earnings Per Share-31.80
Cash And Equivalents Per Share0.66
Cash Per Share0.66
Accumulated Depreciation And Depletion Per Share0.00
Liabilities And Stock Equity Per Share6.92
Additional Paid In Capital Per Share20.16
Minority Interest Per Share0.00
Liabilities Per Share0.46
Equity Per Share6.47
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.07
Long Term Debt Per Share0.00
Assets Per Share6.92
Treasury Stock Per Share0.00
Debt Per Share0.00
Inventory Per Share0.00
Goodwill Per Share0.86
Assets Current Per Share5.38
Intangibles Per Share0.00
Assets Other Non Current Per Share0.04
Deferred Income Tax Liabilities Per Share0.00

Related News Stories

Cascadian Therapeutics: Upside In Other Her2+ Indications

2017-11-21 seekingalpha
Shares have finished flat since my initial piece on the company, but I still believe the stock could do well in the medium term. (20-1)

Tracking Seth Klarman's Baupost Group Holdings - Q3 2017 Update

2017-11-14 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio. (514-7)

Cascadian Therapeutics' (CASC) CEO Scott Myers on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the Cascadian Therapeutics Third Quarter 2017 Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Monique Greer, Senior VP of Corporate Communications. You may begin. (20-0)

Immunomedics: 35 Year History Of Failure, IMMU-132 Will Not Receive Accelerated Approval, 100% Downside Possible

2017-09-20 seekingalpha
We believe that IMMU-132 will not be granted accelerated approval, and IMMU’s mandatory Phase 3 trial will fail, burning through IMMU’s current cash position. Amazingly, IMMU is approaching highest valuation in its entire existence. (142-3)

CUSIP: 14740B101